Avacta announces distribution agreement with abcam plc

Cambridge, england--(business wire)--avacta group plc (aim: avct), the developer of innovative cancer therapies and diagnostics based on its proprietary affimer® and pre|cision™ platforms, is pleased to announce that it has entered into a global distribution agreement with abcam plc (aim: abc; nasdaq: abcm) to sell the group's recently developed sars-cov-2 research elisa affimer® reagents. avacta has developed affimer® reagents which can be used in a high performance elisa laboratory test to de
ABCM Ratings Summary
ABCM Quant Ranking